- Home
- CERS vs XFOR Comparison
CERS vs XFOR Comparison
Compare CERS & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- XFOR
- Stock Information
- Founded
- CERS 1991
- XFOR 2014
- Country
- CERS United States
- XFOR United States
- Employees
- CERS N/A
- XFOR 143
- Industry
- CERS EDP Services
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CERS Technology
- XFOR Health Care
- Exchange
- CERS Nasdaq
- XFOR Nasdaq
- Market Cap
- CERS 276.0M
- XFOR 320.0M
- IPO Year
- CERS 1997
- XFOR N/A
- Fundamental
- Price
- CERS $1.49
- XFOR $3.99
- Analyst Decision
- CERS Buy
- XFOR Strong Buy
- Analyst Count
- CERS 1
- XFOR 3
- Target Price
- CERS $4.00
- XFOR $34.17
- AVG Volume (30 Days)
- CERS 1.2M
- XFOR 1.7M
- Earning Date
- CERS 11-06-2025
- XFOR 11-17-2025
- Dividend Yield
- CERS N/A
- XFOR N/A
- EPS Growth
- CERS N/A
- XFOR N/A
- EPS
- CERS N/A
- XFOR N/A
- Revenue
- CERS $192,510,000.00
- XFOR $32,774,000.00
- Revenue This Year
- CERS $19.07
- XFOR $1,307.51
- Revenue Next Year
- CERS $12.03
- XFOR N/A
- P/E Ratio
- CERS N/A
- XFOR N/A
- Revenue Growth
- CERS 13.25
- XFOR 5721.31
- 52 Week Low
- CERS $1.12
- XFOR $1.35
- 52 Week High
- CERS $2.24
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- CERS 48.79
- XFOR 63.50
- Support Level
- CERS $1.48
- XFOR $2.96
- Resistance Level
- CERS $1.54
- XFOR $4.15
- Average True Range (ATR)
- CERS 0.07
- XFOR 0.27
- MACD
- CERS -0.02
- XFOR 0.09
- Stochastic Oscillator
- CERS 32.14
- XFOR 68.02
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.